Literature DB >> 16764341

Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire.

J M van Noort1, R Verbeek, J F Meilof, C H Polman, S Amor.   

Abstract

Human T-cell responses to the stress protein alpha B-crystallin in multiple sclerosis (MS)-affected brain samples are dominant when compared to other myelin antigens. The establishment of the apparent autoimmune repertoire against this antigen has been suggested to involve cross-priming during viral infection. Yet, another possibility would be that determinant spreading during ocular inflammation could generate a response to alpha B-crystallin, since it is also a major component of the eye. In this study, we compared serum IgG, IgA and IgM repertoires against a range of eye lens-derived ocular antigens using sera from healthy control subjects and MS patients with or without uveitis. This comparison revealed that among ocular antigens, alpha B-crystallin is the dominant target antigen for serum autoantibodies in both MS patients and healthy controls. Uveitis generally did not affect the antibody reactivity profile. These data provide further support for the notion that a normal adult human immune system is selectively reactive to alpha B-crystallin and they indicate that this responsiveness is unlikely to result from determinant spreading following ocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764341     DOI: 10.1191/135248506ms1271oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  11 in total

Review 1.  Extracellular small heat shock proteins: exosomal biogenesis and function.

Authors:  V Sudhakar Reddy; Satish K Madala; Jamma Trinath; G Bhanuprakash Reddy
Journal:  Cell Stress Chaperones       Date:  2017-10-30       Impact factor: 3.667

2.  Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.

Authors:  Jonathan B Rothbard; Xiaoyan Zhao; Orr Sharpe; Michael J Strohman; Michael Kurnellas; Elizabeth D Mellins; William H Robinson; Lawrence Steinman
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

3.  Crystallins and neuroinflammation: The glial side of the story.

Authors:  Jennifer E Dulle; Patrice E Fort
Journal:  Biochim Biophys Acta       Date:  2015-06-03

4.  Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68.

Authors:  Vinita S Chauhan; Daniel A Nelson; Ian Marriott; Kenneth L Bost
Journal:  Autoimmunity       Date:  2013-04-16       Impact factor: 2.815

5.  Functional whole-genome analysis identifies Polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin.

Authors:  Cristina Draghetti; Catherine Salvat; Francisca Zanoguera; Marie-Laure Curchod; Chloé Vignaud; Helene Peixoto; Alessandro Di Cara; David Fischer; Mohanraj Dhanabal; Goutopoulos Andreas; Hadi Abderrahim; Christian Rommel; Montserrat Camps
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

6.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

7.  A potential role of crystallin in the vitreous bodies of rats after ischemia-reperfusion injury.

Authors:  Seong Min Hong; Yun Sik Yang
Journal:  Korean J Ophthalmol       Date:  2012-07-24

Review 8.  Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS).

Authors:  Mirre De Bondt; Niels Hellings; Ghislain Opdenakker; Sofie Struyf
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

9.  Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.

Authors:  Johannes M van Noort; Malika Bsibsi; Peter J Nacken; Richard Verbeek; Edna H G Venneker
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

10.  Antibodies against small heat-shock proteins in Alzheimer's disease as a part of natural human immune repertoire or activation of humoral response?

Authors:  Ewa Papuć; Witold Krupski; Ewa Kurys-Denis; Konrad Rejdak
Journal:  J Neural Transm (Vienna)       Date:  2015-11-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.